Drug Profile
Encequidar/paclitaxel - Hanmi Pharmaceutical
Alternative Names: HM-30181A/paclitaxel - Hanmi Pharmaceutical; HM30181AK; Oraxol; Paclitaxel+HM30181AK; Paclitaxel/encequidar - Hanmi Pharmaceutical; Paclitaxel/HM-30181A - Hanmi Pharmaceutical; Paclitaxel/HM30181-methanesulfonate monohydrate - Hanmi PharmaceuticalLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Breast cancer
- Phase II Cancer; Gastric cancer; Haemangiosarcoma
- Phase I Solid tumours
- No development reported Oesophageal cancer
Most Recent Events
- 02 Jun 2023 Adverse events and efficacy data from a phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease) presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 22 May 2023 Athenex terminates a phase I trial in Solid tumours (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in United Kingdom (PO), due to financial constrains (NCT03892018)
- 12 May 2023 Athenex terminates a phase I clinical trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03588039)